首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal APOBR Antibody

  • 中文名: APOBR抗体
  • 别    名: APOB48R; APOB100R
货号: IPDX13139
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/50-1/100 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/500-1/1000 Human,Mouse,Rat

产品详情

AliasesAPOB48R; APOB100R
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenSynthetic peptide of human APOBR
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

以下是3条关于APOBR抗体的参考文献示例(注:内容为虚构,仅作格式参考):

1. **文献名称**:*Development of a Monoclonal Antibody Targeting APOBR for Lipid Metabolism Studies*

**作者**:Smith J, et al.

**摘要**:该研究开发了一种特异性识别APOBR的单克隆抗体,验证了其在人肝细胞和小鼠模型中的表达,证实APOBR在低密度脂蛋白(LDL)内吞中的关键作用。

2. **文献名称**:*APOBR Antibody-Based Detection in Atherosclerotic Plaque Formation*

**作者**:Chen L, Wang H.

**摘要**:通过免疫组化与Western blot分析,利用新型APOBR抗体揭示了该受体在动脉粥样硬化斑块中的高表达,提示其与炎症反应和脂质堆积相关。

3. **文献名称**:*Functional Characterization of APOBR Using Neutralizing Antibodies in Cellular Models*

**作者**:Garcia R, et al.

**摘要**:研究采用中和性抗体抑制APOBR功能,发现其缺失导致细胞胆固醇摄取效率下降,为APOBR在脂代谢通路中的调控机制提供了实验依据。

(注:实际文献需通过学术数据库检索,建议使用关键词“APOBR antibody”或“Apolipoprotein B receptor”在PubMed、Google Scholar等平台查询。)

背景信息

The apolipoprotein B receptor (APOBR), primarily recognized as the low-density lipoprotein receptor (LDLR), plays a central role in lipid metabolism by mediating cellular uptake of LDL particles containing apolipoprotein B (ApoB). This receptor is critical for maintaining cholesterol homeostasis, as it binds ApoB on LDL, facilitating its endocytosis and subsequent degradation to regulate plasma cholesterol levels. Dysregulation of LDLR/APOBR function is closely linked to hypercholesterolemia and atherosclerosis, making it a key target in cardiovascular research. APOBR-specific antibodies are essential tools for studying receptor expression, localization, and interaction mechanisms. They are widely employed in immunoassays (e.g., Western blot, ELISA), immunohistochemistry, and flow cytometry to investigate LDLR-related pathologies or therapeutic interventions. Monoclonal antibodies targeting APOBR have also been explored for therapeutic applications, such as inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9)-mediated LDLR degradation to lower LDL cholesterol. Additionally, autoantibodies against ApoB-containing lipoproteins have been implicated in autoimmune-related cardiovascular diseases, highlighting their diagnostic and prognostic potential. Research on APOBR antibodies continues to advance insights into lipid disorders and precision therapies for atherosclerosis.

客户数据及评论

折叠内容

大包装询价

×